ABSTRACT
The difference between the walking speeds of stroke patients and the general population may influence the self-perception of patients, who perceive their walk as lacking general human-likeness. Perception toward human-likeness during walking is defined here as the feeling that one can walk as intended, just like healthy people. Such negative subjective experiences may curb their social participation. However, the perception associated with walking speed in stroke patients is poorly understood. The main purpose of this study was to investigate the relationship between walking speed and perception toward general human-likeness during walking in stroke patients. Thirty-two post-stroke patients were enrolled in this cross-sectional study. Patients performed 10-m walk tests at comfortable and fast speeds and answered questions about their perceived human-like walking after completing the walk ("How much did you feel your walking resembled the human-likeness during walking of general people?"). We found a significant positive correlation between perception toward human-likeness during walking and walking speed at both comfortable and fast speeds. To the best of our knowledge, this report is the first to suggest that walking speed may correlate with self-perception. Our findings may help understand the underlying mechanism in patients perceiving less human-likeness during walking.
ABSTRACT
BACKGROUND: Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number, and duration of drugs used to treat MDR-TB. METHODS AND FINDINGS: Three recent systematic reviews were used to identify studies reporting treatment outcomes of microbiologically confirmed MDR-TB. Study authors were contacted to solicit individual patient data including clinical characteristics, treatment given, and outcomes. Random effects multivariable logistic meta-regression was used to estimate adjusted odds of treatment success. Adequate treatment and outcome data were provided for 9,153 patients with MDR-TB from 32 observational studies. Treatment success, compared to failure/relapse, was associated with use of: later generation quinolones, (adjusted odds ratio [aOR]: 2.5 [95% CI 1.1-6.0]), ofloxacin (aOR: 2.5 [1.6-3.9]), ethionamide or prothionamide (aOR: 1.7 [1.3-2.3]), use of four or more likely effective drugs in the initial intensive phase (aOR: 2.3 [1.3-3.9]), and three or more likely effective drugs in the continuation phase (aOR: 2.7 [1.7-4.1]). Similar results were seen for the association of treatment success compared to failure/relapse or death: later generation quinolones, (aOR: 2.7 [1.7-4.3]), ofloxacin (aOR: 2.3 [1.3-3.8]), ethionamide or prothionamide (aOR: 1.7 [1.4-2.1]), use of four or more likely effective drugs in the initial intensive phase (aOR: 2.7 [1.9-3.9]), and three or more likely effective drugs in the continuation phase (aOR: 4.5 [3.4-6.0]). CONCLUSIONS: In this individual patient data meta-analysis of observational data, improved MDR-TB treatment success and survival were associated with use of certain fluoroquinolones, ethionamide, or prothionamide, and greater total number of effective drugs. However, randomized trials are urgently needed to optimize MDR-TB treatment. Please see later in the article for the Editors' Summary.
